Mauricio Burotto
@BurottoMauricio
Followers
230
Following
907
Media
10
Statuses
446
Internal Medicine Medical Oncologist
Santiago de Chile
Joined June 2018
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. https://t.co/0vqWHuJ9tm
3
31
90
Antibody–drug conjugates in combination therapy: defining the next chapter☆ - Annals of Oncology https://t.co/2wSBonrMd4
@Annals_Oncology @myESMO @tompowles1 @OncoAlert
0
23
52
Lots of ❓s in defining benefits of “#oligomet” or “#MDT” therapy in #ProstateCancer ❓ADT+/-ARPI? How long? ❓PFS vs Eugonadal PFS? ❓how many mets? Where? 🔑❓what imaging 🩻❓ #PSMA mets🚫🟰CT/Bone scan mets https://t.co/LFMdSkoVln Std of Care? Or just something we can do?
2
15
30
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations @theNCI
#BCR #ProstateCancer #ClinicalTrial
https://t.co/ePbf8j7KQU
1
8
14
ROME study @NatureMedicine randomized targeted therapy vs standard of care after molecular analysis (tissue/blood) in pretreated cancer patients across tumors. ⬆️ORR (17.5% vs 10%) & ⬆️PFS HR=0.66, but no OS (HR 0.92). OS feels important despite crossover ~45% . Congrats 🥳
2
38
107
PSA: Stop calling macrophages in tissue M1 or M2. These are not states that exist in biology. The only use of M1 is a macrophage cultured ex vivo with LPS and IFNg; and for M2: IL-4/13/10. Macrophages in tissues are highly complex and diverse and do not resemble either of the
32
175
940
Lots of exciting updates in the management of #BladderCancer at multiple stages. We highlight the multiple trials in the perioperative setting for muscle-invasive disease including ✅NIAGARA Pending: ☑️EV 303 & 304 ☑️ ENERGIZE ☑️ KEYNOTE 866 ☑️ VOLGA https://t.co/jR4OdOwCLt…
The outlook for the #BladderCancer field is undoubtedly positive as the field builds upon an excellent foundation of novel therapeutics and drug delivery mechanisms. Hear more from @apolo_andrea, lead author of a recent commentary in Cancer: https://t.co/Rm7JZKrxGr
@OncoAlert
1
24
71
Important to distinguish #serosal findings on #PSMA 🩻vs. #parenchymal Serosal lesions are better seen on #PSMA vs CT/MRI in #ProstateCancer but likely have an indolent course even with no 🚫therapy (even on the liver!) @melissaabel20 et al.@NatRevUrol
https://t.co/UQ3gKEczvJ
2
13
23
🧪 A step forward in bladder-sparing strategies for MIBC. An international consensus defines clinical complete response (cCR) and proposes event-free survival (EFS) as the preferred endpoint in next-gen perioperative trials. #BladderCancer @OncoAlert @JCO_ASCO
2
27
54
Huge congrats to @DrYukselUrun , @coskunyazgann @drdeniztural @nataliagandur and all the team for their effort and contribution to this great real-world data: ARON-3 data in mCRPC: 🎯 285 pts on [177Lu]PSMA vs 283 cabazitaxel ✅ Higher PSA50/90 response ✅ Longer OS & TTF with
2
14
45
📬 The Milan Consensus paper on Clinical CR definition & Endpoints for next-gen bladder-sparing trials is out in @JCO_ASCO @ASCO | following the @SanRaffaeleMI #GURetreat24 Co-sponsored by @IBCG_BladderCA @GTumors It was a tremendous multidisciplinary effort involving
3
40
96
💫🌟📢 @Annals_Oncology – #KEYNOTE-641 Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide in chemo-naïve mCRPC @OncoAlert @APCCC_Lugano Julie N. Graff, @BurottoMauricio, @PeterCFong, @docpook @AStenzl – on behalf of the KEYNOTE-641 Investigators. 📊 Results: ➡️ OS: 24.7 vs
1
11
22
Looking forward to update this data @myESMO next month on the indolent nature of #PSMA+ #BCR
@melissaabel20 @EdwinPosadasMD @RPachynski @laurasenamd @CathyHandy @Dr_JeannyAC @mbilusic @FatimaKarzai @HelenMoonMD @PCF_Science
PSMA PET in biochemical recurrence: When to treat vs when to wait. @Dr_RaviMadan @theNCI joins @TiansterZhang @UTSWMedCenter to discuss a prospective study monitoring PSMA PET-positive biochemically recurrent prostate cancer patients. #WatchNow on UroToday >
0
4
17
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study - Journal of Thoracic Oncology
jto.org
We present the LEAP-006 (NCT03829319) phase 3 study evaluating the addition of lenvatinib to first-line pembrolizumab plus chemotherapy in metastatic nonsquamous NSCLC.
0
1
2
@oncology_bg “What are the benefits of defining “PD” [w/#PSMA] earlier outside of the illusion of being proactive?….as oncologists it is our role to educate pts about the bigger picture & pragmatic realities of diminishing therapeutic returns...” #prostatecancer
https://t.co/pICCWgnQf6
ascopubs.org
0
1
1
New #JITC position article and guidelines: Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee https://t.co/kunHIhqwV4
@Nora_Sobrevilla
@ThomasUldrick @JyotiBajpai01
0
4
10
Thank you @UroToday & DrSartor for the opportunity to discuss a commentary in @JCO_ASCO w/@RickLee6 @EdwinPosadasMD @FatimaKarzai @PChoyke & #EvanYu @fredhutch ⚠️There is danger & no🚫data supporting #PSMA #PET 🩻restaging in #mCRPC #ProstateCancer⚠️ 🔗
ascopubs.org
PSMA PET in #ProstateCancer: Balancing Sensitivity and Clinical Relevance. @Dr_RaviMadan @theNCI joins Oliver Sartor, MD @MayoClinic to discuss the implications of using PSMA PET scans in #mCRPC. #Watch the full interview on UroToday > https://t.co/hqeE73KaDd
0
8
40
Reporte colaborativo sobre estudios clínicos de IO en regiones como Sudamérica
jitc.bmj.com
Cancer is rapidly on the rise as a cause of morbidity and mortality in low- and middle-income countries (LMICs). However, despite the increasing importance of immune checkpoint inhibitors (ICIs) as a...
0
0
1
Sadly this is 💯 correct @ProtonStorey We are also repeating the mistakes made a generation ago with Gleason 6 #ProstateCancer and now applying it to the #BCR/#PSMA+ #BCR setting. Overreacting to disease that may not be clinically relevant for many yrs @urotoday
American physicians love tests and just doing stuff. We are currently repeating the mistakes of PSA leading to too many downstream un-needed procedures with PSMA scans.
1
3
2
CheckMate 901 Nivolumab plus ipilimumab vs gemcitabine-carboplatin chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma Presented at #ASCO25
https://t.co/TsR8kmswqO In the phase 3 CheckMate 901 trial, nivolumab plus ipilimumab (NIVO+IPI) was
0
15
28